title: [Liposomal-amphotericin B efficacy and safety].
abstract: Liposomal amphotericin B (L-AMB), a lipid-based amphotericin B formulation, has been used in Japan since June 2006 to treat fungal infection. In the 3 years since L-AMB was launched, few reports have been made on its status. To ensure its appropriate use, we restrospectively reviewed its efficacy and safety in treating fungal infections. 25 subjects with fungal infection treated with L-AMB from April 2007 until February 2008. Of those, 16 showed clinical improvement. Elevated serum creatinine occurred in 1 and decreased serum potassium in 6. We found a positive relationship between the serum potassium decrease and L-AMB dose. Logistic regression analysis of this relationship showed that serum potassium tended to fall on day 5 to 6 of L-AMB administration. While L-AMB appears highly effective in fungal infection, it requires serum potassium monitoring to ensure patient safety.
authors.affiliation: Department of Pharmacy, Kitasato University Hospital.
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Hamada
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Komatsu
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Seto
authors.forename: Hajime
authors.initials: H
authors.lastname: Matsubara
authors.forename: Hikaru
authors.initials: H
authors.lastname: Kume
authors.forename: Keisuke
authors.initials: K
authors.lastname: Sunakawa
authors.forename: Kazuo
authors.initials: K
authors.lastname: Yago
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008081:Liposomes; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D000935:Antifungal Agents; D008081:Liposomes; D000666:Amphotericin B